Aclarion Inc (ACON)vsVeeva Systems Inc Class A (VEEV)
ACON
Aclarion Inc
$3.45
+10.58%
HEALTHCARE · Cap: $3.58M
VEEV
Veeva Systems Inc Class A
$178.11
-0.56%
HEALTHCARE · Cap: $29.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Veeva Systems Inc Class A generates 5075851% more annual revenue ($3.20B vs $62,950). VEEV leads profitability with a 28.4% profit margin vs 0.0%. VEEV earns a higher WallStSmart Score of 69/100 (B-).
ACON
Avoid33
out of 100
Grade: F
VEEV
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACON.
Margin of Safety
+25.9%
Fair Value
$238.92
Current Price
$178.11
$60.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 76.1% year-over-year
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Growing faster than its price suggests
Strong operational efficiency at 29.4%
16.0% revenue growth
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -88.3% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ACON
The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 76.1% demonstrates continued momentum.
Bull Case : VEEV
The strongest argument for VEEV centers on Debt/Equity, Profit Margin, PEG Ratio. Profitability is solid with margins at 28.4% and operating margin at 29.4%. Revenue growth of 16.0% demonstrates continued momentum.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Bear Case : VEEV
The primary concerns for VEEV are P/E Ratio.
Key Dynamics to Monitor
ACON profiles as a hypergrowth stock while VEEV is a growth play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.43 — expect wider price swings.
ACON is growing revenue faster at 76.1% — sustainability is the question.
VEEV generates stronger free cash flow (100M), providing more financial flexibility.
Bottom Line
VEEV scores higher overall (69/100 vs 33/100), backed by strong 28.4% margins and 16.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is an innovative healthcare technology company specializing in non-invasive diagnostic solutions that harness advanced data analytics and machine learning. By optimizing treatment pathways for musculoskeletal conditions, Aclarion delivers actionable insights derived from cutting-edge imaging techniques. Positioned at the forefront of the digital health sector, the company is addressing significant challenges in patient management while enhancing outcomes and reducing costs. Aclarion is well-positioned to capitalize on the growing demand for effective diagnostic tools in a dynamic healthcare landscape.
Visit Website →Veeva Systems Inc Class A
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?